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Asbestos and related ﬁbers are associated with a number of adverse health effects, including
malignant mesothelioma (MM), an aggressive cancer that generally develops in the surface
serosal cells of the pleural, pericardial, and peritoneal cavities. Although approximately 80%
of individuals with MM are exposed to asbestos, fewer than 5% of asbestos workers develop
MM. In addition to asbestos, other mineralogical, environmental, genetic, and possibly viral
factors might contribute to MM susceptibility. Given this complex etiology of MM, under-
standing susceptibility to MM needs to be a priority for investigators in order to reduce
exposure of those most at risk to known environmental carcinogens. In this review, the cur-
rent body of literature related to ﬁber-associated disease susceptibility including age, sex,
nutrition, genetics, asbestos, and other mineral exposure is addressed with a focus on MM,
and critical areas for further study are recommended.
This review is a post-meeting white paper
summarizing the role of factors that inﬂu-
ence susceptibility to mineral ﬁber-induced
adverse health effects for the meeting enti-
tled “Asbestos: A Science-Based Examination
of the Mode of Action of Asbestos and
Related Mineral Fibers,” sponsored by the
National Institute of Environmental Health
Sciences (NIEHS), Agency for Toxic Substances
and Disease Registry (ATSDR), and U.S.
Environmental Protection Agency (EPA). The
meeting was held December 16–18, 2009, in
Research Triangle Park, NC, and the overall
goal of the workshop was to review the litera-
ture on various areas related to asbestos expo-
sure with some key questions in mind. These
questions relate to the current state of asbestos
research, the level of consensus in the ﬁeld,
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and the areas that require more investigations.
Part of this effort is to stimulate research in
these areas, as well as to determine the current
state of the science particular to the area of
susceptibility to ﬁber-induced disease.
The team addressing susceptibility to
asbestos was assigned to consider the main fac-
tors that impact susceptibility to ﬁber-induced
adverse health effects, including age, gender
and disease status, genetics, and nutrition, as
summarized in the following. It is notewor-
thy that the term “asbestos” often refers to a
family of six different ﬁber types (the amphi-
boles amosite, crocidolite, tremolite, actino-
lite, and anthophyllite, and the serpentine
chrysotile), each with markedly different miner-
alogical characteristics and associated adverse
health effects. The complexity of deﬁning
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asbestos minerals, and ﬁbers in general, has
led to inconsistencies in the scientiﬁc literature
(Addison and McConnell 2008). For the pur-
poses of this review, the discussions include
studies of asbestos minerals and asbestos-
like ﬁbers beyond those listed in this deﬁ-
nition. A number of epidemiological studies
have primarily associated malignant mesothe-
lioma (MM) with exposure to amphibole-type
asbestos ﬁbers, which generally are more per-
sistent and durable in lung than chrysotile;
however, to varying degrees, all ﬁber types have
been associated with cancer and MM suscep-
tibility (Berman and Crump 2008; Hodgson
and Darnton 2000). Although ﬁber-induced
adverse health effects extend beyond MM sus-
ceptibility, this review, reﬂective of the litera-
ture, primarily focuses on MM.
AGE AND SEX IN FIBER-RELATED
DISEASE
Although it is well known that males
and females display signiﬁcant differences in
responses to environmental insults, gender
effects have received relatively little attention in
molecular epidemiological studies on environ-
mentally induced diseases. Often gender has
been viewed as a confounder rather than a fac-
tor of primary importance. Indeed, practically
no data exist on the possible role of factors
such as age, gender, and disease status in the
development of asbestos-related nonmalignant
disorders or lung cancer. In contrast, there are
extensive data indicating that both occupa-
tional and environmental exposures play an
important role in the onset of and survival
from MM.
MM was shown to occur more frequently
in men than in women (Antman et al., 2001).
The wide disparity between males and females
in the incidence of MM is clearly illustrated by
a recent analysis of cases in the United States
from 1975 to 2004 based on the Surveillance,
Epidemiology and End Results (SEER) Program
(Cook et al., 2009). In the analysis, MM was
ranked fourth in the list of 10 cancers with
the largest male-to-female incidence rate ratios
(IRR). The IRR for MM was 4.9, and was pre-
ceded only by Kaposi sarcoma (28.7), lip (7.2),
and larynx (5.2). Occupational exposure to
asbestos in male-dominated professions, such
as pipe ﬁtting, construction, shipyard work, and
asbestos mining, is strongly associated with risk
(Astoul, 2003), and a recent analysis of cancer
risk in 15 million people in 5 Nordic coun-
tries found MM to have the largest relative
differences between the occupations (Pukkala
et al., 2009). Thus, the observed gender-related
differences in MM incidence may well be
claimed to be largely due to occupational rea-
sons; however, since low levels of exposure
to MM-associated carcinogens are sufﬁcient
to lead to tumorigenesis, it has been difﬁ-
cult to assess susceptibility differences between
genders (Astoul, 2003). The question stills
remains, how do males and females differ
in regard to onset of disease and outcome
if both have experienced same equivalent
exposures? Understanding the potential mech-
anisms underlying gender-related differences
in response to asbestos-exposure are there-
fore critical to the development of improved
primary prevention strategies and possibly to
more adequate therapies.
The genetic variations responsible for the
gender-related differences in sensitivity to envi-
ronmental agents may result from different
hormonal environments and/or be evident
in sex-speciﬁc organs. As for chromosomal
changes, it is known that X-chromosome
loss occurs with age in women. This was
demonstrated in several epidemiological stud-
ies assessing micronuclei (MN) frequencies in
women versus men (Hando et al., 1994;
Surralles et al., 1996; 1999). MN are small
amounts of DNA that arise in the cytoplasm
when chromatid/chromosomal fragments are
not incorporated into daughter nuclei dur-
ing mitosis, often because these fragments do
not possess a centromere (Schmid, 1975). It
is also known that the inactive heterochro-
matic X-chromosome is lost preferentially, and
thus the few genes transcribed from this het-
erochromatic X-chromosome might contribute
to sex effects. The importance of loss of the
X-chromosome to gender-related differences
in sensitivity to environmental carcinogens is
uncertain, as loss of the Y-chromosome occurs
with age in males.248 J. E. BELOW ET AL.
Although no clear evidence is available that
differences exist between females and males
in the susceptibility to genotoxic exposure or
in the mechanisms underlying disease etiology
and pathogenesis, differences between genders
in hormonal status and reproductive factors
have well-established inﬂuences on some can-
cers (Higginson et al., 1992), in addition to
tobacco smoking and job tasks and associated
occupational exposures.
Moreover, epigenetic mechanisms, which
have not yet been well studied in relation
to asbestos-induced susceptibility, may also
contribute to the differential susceptibility to
MM between men and women (Kaminsky
et al., 2006); although the methylation dif-
ference of a large number of CpGs analyzed
on three human chromosomes identiﬁed a
relatively small mean methylation difference
(0.1%) between males and females (Eckhardt
et al., 2006), these small differences in methy-
lation patterns, if present at critical regula-
tory genes, may exert signiﬁcant impact on
cellular response to environmental exposure.
DNA methylation changes in sex hormone
genes and/or the gene targets of sex hor-
mones may be considered as a potential epi-
genetic mechanism underlying gender-speciﬁc
response to environmental insults. Sex hor-
mones are known to be potent modulators
of speciﬁc genes and genomic functions, and
increasing evidence suggests that sex hormones
modify gene expression through local recon-
ﬁguration of epigenetic states (Sawan et al.,
2008). Different epigenetic mechanisms also
appear to cross-inﬂuence and reinforce each
other in the orchestration of cellular response
to environmental stimuli and endogenous cues
(Sawan et al., 2008; Vaissiere et al., 2008).
In addition to higher incidence of MM,
male gender has also been associated with
poor prognosis of MM. Moreover, age at
diagnosis, work exposure, age at ﬁrst expo-
sure, histological subtype, and stage of disease
are considered to deﬁne a phenotype that
sets MM patients with a shortened survival
apart from other asbestos-exposed individuals
(Boutin et al., 1993; De Pangher Manzini et al.,
1993; Van Gelder et al., 1994; Ceresoli et al.,
2001; Neumann et al., 2004; BTS statement
on malignant mesothelioma in the UK, 2007;
Ohar et al., 2007; Montanaro et al., 2009).
Recently, the prognostic signiﬁcance of lymph
nodal involvement in this disease was also
deﬁned; absence of lymph node metastasis was
strongly associated with improved survival (Yan
et al., 2006).
However, there appears to be a great deal
of conﬂicting data on the importance of some
of these prognostic factors. For instance, the
value of patient age in predicting a poor out-
come has been challenged (Ohar et al., 2007);
at least four studies showed that age is not
of importance in this context (Samson et al.,
1987; Rusch et al., 1991; Tammilehto, 1992;
Boutin et al., 1993), whereas several others
suggested that age is an important predictor
(Chahinian et al., 1982; De Pangher Manzini
et al., 1993; Antman et al., 1988; Calavrezos
et al., 1988; Spirtas et al., 1988; Rufﬁe et al.,
1989).
Somewhat surprisingly, there have been
several conﬂicting reports with regard to the
importance of stage as a prognostic marker
(Samson et al., 1987; Antman et al., 1988;
Curran et al., 1998). The main reason for this
may be the problems with the existing staging
systems. To obtain complete clinical informa-
tion, patients need to have had cytoreductive
surgery such as an extrapleural pneumonec-
tomy. However, most patients are not able
to have this operation. Consequently, stag-
ing data based on radiological ﬁndings that
are reported in nonsurgical series are likely to
be less reliable estimates. As expected, two
large surgical series (Rusch & Venkatraman,
1999; Sugarbaker et al., 1999) conﬁrmed that
patients staged surgically as stage I or II survive
longer than those with advanced stages of MM.
IONIZING RADIATION IN MM
Goodman et al. (2009) published a review
of the literature relating the effects of ioniz-
ing radiation with MM risk. Ionizing radiation
is known to be a human carcinogen and linked
to several cancer types (Abbatt, 1979). A review
of the literature supports multiple types of
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MM cases among individuals exposed to α-a n d
β-emitters in Thorotrast treatment, γ treatment
(60Co and X-ray radiotherapy), and occupa-
tional γ radiation (Goodman et al., 2009).
However, it is difﬁcult to exclude the possibility
of asbestos exposure in radiation-exposed indi-
viduals, and not all studies reviewed reached
a statistically signiﬁcant level of association.
The role of ionizing radiation in MM remains
suggestive and warrants further investigation.
ENVIRONMENTAL EXPOSURES IN MM
MM is a rare, aggressive cancer that is
generally found in populations exposed to
asbestos (Pass et al., 2004; Astoul, 2003).
Although the primary cause of MM is expo-
sure to asbestos ﬁbers (Price, 1997; Carbone
et al., 2002; Wagner et al., 1960), other min-
eralogical (Bertino et al., 2007), radiological
(Goodman et al., 2009), and viral exposures
(Carbone et al., 2008; Gazdar et al., 2002;
Rivera et al., 2008), as well as genetic factors,
are thought to contribute to MM susceptibil-
ity (Huncharek et al., 1996; Huncharek, 1995;
2002; Ascoli et al., 1998; Dogan et al., 2006;
Roushdy-Hammady et al., 2001). Risks associ-
ated with exposure to speciﬁc types of minerals
are difﬁcult to parse; even given environmental
and occupational measures of ﬁber concen-
tration and phase-contrast light microscopy of
bronchoalveolar lavage ﬂuid, it can be difﬁcult
to address ﬁber-speciﬁc risks given differen-
tial alveolar clearance of ﬁbers by type and
dimension.
BIOMARKERS IN MM
Due to the rapid progression and high
mortality rate associated with MM, identiﬁca-
tion of a predictive biomarker to screen for
individuals at greater risk of developing MM
would be useful in studies of tumorigenesis
and treatment. Because of recent advances
in chemotherapeutic agents that may prolong
survival and the potential beneﬁts of biomark-
ers as diagnostic, monitoring, and screening
tools, there has been strong interest in iden-
tifying a marker having both high speciﬁcity
and high sensitivity (Scherpereel & Lee, 2007).
In 2003, Robinson et al. (2003) reported that
in 7 of 40 asbestos-exposed individuals who
tested positive for elevated soluble mesothelin-
related peptide (SMRP)/megakaryocyte poten-
tiating factor (both encoded by the same
gene), 3 were diagnosed with MM within 3 yr.
None of the 33 subjects with normal levels of
SMRP developed MM within 8 yr of follow-
up study (Pass et al., 2008; Scherpereel & Lee,
2007; Cristaudo et al., 2007). In addition to
SMRP (Creaney et al., 2007; Robinson et al.,
2003) osteopontin (Pass et al., 2005, 2008;
Scherpereel & Lee, 2007; Cristaudo et al.,
2006, 2007), and MN/CA9 (Li et al., 2007) are
all promising biomarkers for MM. However, no
one marker is speciﬁc for MM. For example,
elevated SMRP levels are sometimes observed
in lung cancer patients and healthy, asbestos-
exposed individuals. Genetic factors may play
a role in population variation of biomarker lev-
els; such potentially confounding factors need
to be identiﬁed to improve the clinical utility
of biomarkers for MM (Cristaudo et al., 2010).
A well-characterized biomarker for MM may
also be useful in identiﬁcation of a genetic
susceptibility factor by providing an additional
quantitative phenotype for use in association
and linkage analyses as well as increasing the
number of samples that meet inclusion criteria.
GENETIC SUSCEPTIBILITY IN
FAMILIAL MM
Although many have considered MM the
archetype of environmentally induced cancers,
familial incidence and low rate among even
those most heavily exposed to known MM-
speciﬁc carcinogens point to a more complex
etiology. Given the low incidence of MM, the
likelihood of observing multiple cases of this
disease in an unexposed family in the absence
of a genetic susceptibility factor is exceed-
ingly rare. Recent reviews of the literature
available in the PubMed database (PubMed,
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U.S. National Library of Medicine) have come
to contrasting conclusions on the likely effect
of a genetic susceptibility factor. Ascoli et al.
(2007) reviewed data from 33 publications
spanning 1968–2005 in Medline, Toxline, and
Oshline/Hseline databases, including 51 fam-
ily clusters and 120 cases of MM among blood
relatives. In addition, Ascoli et al. (2007) noted
11 newly identiﬁed family clusters from three
Italian mesothelioma registries. The observa-
tion of MM in spouses as well as blood relations
and lack of recurrent chromosomal aberrations
in these families led them to conclude that
there is a lack of evidence to support an inﬂu-
ential genetic susceptibility factor. Ugolini et al.
(2008) summarized 20 reports of MM among
blood relations in the PubMed database from
1960 to 2007, ﬁnding that shared exposures
were not sufﬁcient to account for the cluster-
ing, and concluded that a polygenic factor was
likely at play. In fact, in some instances, in one
or more cases within the family no direct expo-
sure to a toxic ﬁber was identiﬁed (Bisconti
et al., 2000; Ugolini et al., 2008; Lynch et al.,
1985). While the conclusions of Ascoli et al.
(2007) and Ugolini et al. (2008) differ, in fact
both suggest that there is insufﬁcient evidence
to implicate a single genetic susceptibility locus.
It is likely that reviews of MM cases in
other exposed populations may reveal addi-
tional familial clusters of the disease. Genetic
LINKAGE analysis on germline DNA in families
has the potential to elucidate genetic regions
contributing to risk. An extensive collabora-
tion and databank are necessary to aggregate
information and DNA samples for large-scale
cross-family LINKAGE analyses.
FIBER-RELATED DISEASE
SUSCEPTIBILITY IN LIBBY, MT
Vermiculite from a mine near Libby, MT,
is contaminated with tremolite asbestos and
other amphibole ﬁbers. Asbestos-contaminated
Libby vermiculite was used in loose ﬁll attic
insulation that remains in millions of homes in
the United States, Canada, and other coun-
tries, and a historical cohort mortality study
revealed that Libby workers were signiﬁcantly
more likely to die from asbestosis, lung can-
cer, and MM (Sullivan, 2007). To date, more
than 30 cases of MM resulting from exposure
to asbestos-containing vermiculite have been
identiﬁed from Libby, MT (Whitehouse et al.,
2008). Included in this group are 11 in non-
occupationally exposed people, appearing to
have developed disease from exposure to con-
tamination of the community and surrounding
areas in proximity to the railroad tracks used
to haul vermiculite. The cumulative exposures
in this area are considered to be similar to
those in Western Australia’s crocidolite mine at
Wittenoom Gorge.
ERIONITE IN AN MM EPIDEMIC
In Cappadocia, Turkey, a region of Central
Anatolia, there are 3 villages (Karain: popu-
lation approximately 600, Tuzkoy: population
approximately 1400, and the abandoned vil-
lage “Old” Sarihidir: population approximately
250 in the 1960s prior to abandonment) in
which 50% or more of all deaths are caused
by MM (Baris et al., 1978; 1996; Carbone
et al., 2002; Baris & Grandjean, 2006). An
international collaboration has undertaken a
major research initiative to characterize sus-
ceptibility and disease etiology in this region
in an effort to understand and curtail this epi-
demic (Carbone et al., 2007). Although some
asbestos was found in the region (Rohl et al.,
1982), it was determined that asbestos could
not account for the MM epidemic, since neigh-
boring villages with similar levels of asbestos did
not experience the high incidence of MM (Baris
et al., 1987; Carbone et al., 2002). Indeed,
nearby villages such as Karlik, which is only
1.5 miles away from Karain, are not experienc-
ing an excess incidence of MM (Baris et al.,
1981). The causative agent was identiﬁed as
erionite (Baris et al., 1979, 1987; Sebastien
et al., 1981; Coplu et al., 1996), a member
of the zeolite family of mineral ﬁbers originat-
ing from a local volcanic tuff that is quarried
by villagers for use in the construction of their
homes (Carbone et al., 2002; Baris et al., 1987,
1996). This association is strongly supported by
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asbestos-exposed populations such as plaques,
calciﬁcations (Baris et al., 1978; Baris, 1991),
and ferruginous bodies which contained eri-
onite ﬁbers (Sebastien et al., 1981; Dumortier
et al., 2001).
Erionite was found to induce MM in
rodents both by injection into the pleural or
peritoneal cavities and by inhalation (Wagner
et al., 1985; Johnson et al., 1984; Maltoni
et al., 1982; Van der Meeren et al., 1992).
Further investigations in rodents showed that
erionite disrupts the balance between cell
proliferation and apoptosis toward cell pro-
liferation. In addition, only small amounts of
erionite (compared to crocidolite asbestos) are
necessary to stimulate c-jun proto-oncogene
expression, a known mechanism of ﬁber
carcinogenesis (Timblin et al., 1998). Most
recently, erionite was found to transform
human mesothelial cells into highly prolifer-
ating tumor cells (Bertino et al., 2007). The
incidence of all other tumor types is similar in
these villages and the rest of Turkey, suggesting
that erionite acts speciﬁcally on MM carcino-
genesis (Carbone et al., 2002; Emri et al.,
2002).
Because erionite is present within villages,
such as Karlik, in measurable quantities in
air samples taken above the streets (Baris
et al., 1981) and all homes contained sim-
ilar amounts of erionite (Roushdy-Hammady
et al., 2001), it is reasonable to expect all res-
idents within a village to have similar risk of
MM. Yet within towns experiencing the epi-
demic, MM occurs predominantly in speciﬁc
families, with no development of the disease
in neighboring families (Carbone et al., 2002;
Roushdy-Hammady et al., 2001).
Evidence of familial MM is not limited to
rural Turkey nor to erionite exposure (Risberg
et al., 1980; Lynch et al., 1985; Munoz et al.,
1988;Otteetal.,1990;Martenssonetal.,1984;
Hammar et al., 1989; Dawson et al., 1992;
Li et al., 1978, 1989; Huncharek, 1995;
Huncharek et al., 1996; Ascoli et al., 1998).
Furthermore, erionite, now considered to be
the most potent known chemical carcinogen
in humans by the International Agency for
Research on Cancer, is present in the United
States, including Arizona, California, Idaho,
Nevada, New Mexico, North Dakota, Oregon,
Texas, Utah, and Wyoming (Virta, 2006).
Although few North American cases of erionite-
associated MM have been reported in the
literature (Kliment et al., 2009), research to
understand the impact of these exposures to
susceptibility in areas within the United States
is necessary.
GENETIC FACTORS IN AN MM
EPIDEMIC
Preliminary pedigree analysis demonstrates
that in these villages, MM is common in
some families (Roushdy-Hammady et al., 2001)
but not in others, consistent with a genetic
contribution to susceptibility. A 6-generation
extended pedigree (in which MM showed
clear familial clustering) of 526 individuals from
Tuzkoy was constructed from kinship maps.
Analysis revealed that when high-risk MM fam-
ily members marry into a low-risk family, MM
appears in approximately 50% of the descen-
dents. Further, 41 of 87 children with at least
1 affected parent had MM. Both of these ﬁnd-
ings are suggestive of an autosomal dominant
mode of transmission with reduced penetrance
(Figure 1), due perhaps to gene–environment
interaction (Carbone et al., 2002; Roushdy-
Hammady et al., 2001), although there is
debate over the methods and interpretation of
the study (Saracci & Simonato, 2001; Ascoli
et al., 2001). Interestingly, MM does not seem
to develop in members of high-risk families
born and raised outside these villages (Carbone
et al., 2002), supporting the postulation that
an environmental trigger may be necessary
to induce susceptibility. These observations
support a model of interacting genetic and
environmental factors in the susceptibility of
Cappadocian villagers to MM.
The level of disease complexity places MM
in the group of diseases that present the great-
est challenges currently in the ﬁeld of disease
genetics, such as type 2 diabetes, asthma,
or cardiovascular disease. MM in Cappadocia
is uniquely situated among complex diseases252 J. E. BELOW ET AL.
FIGURE 1. (A, B) Representative three-generation pedigrees taken from a single large pedigree of villagers from Cappadoccia, showing
the vertical transmission pattern of MM. Black circles/squares represent affected females/males, respectively. Top-ﬁlled square represents
liver cancer; bottom-ﬁlled circle represents pleural thickening. Ages of individuals in 2001 or ages at death are shown next to each
symbol, when known (Roushdy-Hammady et al., 2001).
because of the large pedigrees, extensive geno-
typing, and careful measurements of known
environmental susceptibility factors. In addi-
tion, this epidemiological story stands alone
because of the characteristics of the popula-
tion; for example, there is likely allelic and
environmental homogeneity within this iso-
lated and potentially inbred population, as
well as many related affected individuals.
These data pave the path to new analyti-
cal approaches, building upon and extending
methods widely used in the ﬁeld of computa-
tional genetics.
The identiﬁcation of the putative MM sus-
ceptibility gene(s) in a single population, such
as Cappadocian villagers, will prompt studies
to determine whether the same genes con-
fer susceptibility to familial MM elsewhere
in the world and/or contribute to tumor
onset or progression in sporadic cancers. The
same gene product(s) may act in a common
pathway with the environmental susceptibil-
ity factors: asbestos, and potentially SV40. In
addition, identiﬁcation of a genetic defect lead-
ing to predisposition to MM might lead to the
development of preventative and therapeutic
approaches that may beneﬁt many patients
across industrialized nations.
RECURRENT CHROMOSOMAL
ABBERATIONS IN FIBER-RELATED
TUMOR TISSUE
There is a long latency between expo-
sure and MM development. A meta-analysis
of 21 studies of 1690 cases of MM found
that 96% of cancers occurred at least 20 yr
after initial exposure, with a mean latency of
32 yr (Lanphear & Buncher, 1992). Murthy
and Testa (1999) suggested that such a long
latency from the time of exposure to the
onset of disease may indicate that multiple
genetic events are required for mesothelial
cell transformation. Indeed, while no single
chromosomal change is shared by all MM,
several sites of recurrent deletion were noted
that harbor known tumor suppressor genes,
and karyotypic analyses of tumors revealed
multiple clonal cytogenetic changes, includ-
ing aneuploidy, deletions, and rearrangements
such as unbalanced translocations (Murthy and
Testa, 1999; Musti et al., 2006; Testa and
Jhanwar, 2003; Gibas et al., 1986; Popescu
et al., 1988; Tiainen et al., 1988; Flejter et al.,
1989; Hagemeijer et al., 1990; Taguchi et al.,
1993; Serio et al., 2009; Neragi-Miandoab &
Sugarbaker, 2009; Factor et al., 2009; Ivanov
et al., 2009; Taniguchi et al., 2007). Using
chromosome banding, ﬂuorescence in situ
hybridization, and metaphase-based compar-
ative genomic hybridization analysis, recurring
alterations were observed on multiple chromo-
somes, including chromosomes 1, 3, 4, 6, 9,
11, 13, 14, 15, 17, and 22; moreover, sev-
eral critical regions, including 1p22, 3p21, 6q,
9p21, 15q11.1–15, and 22q12, were identiﬁed
and explored as sites harboring putative tumor
suppressor genes (Murthy & Testa, 1999).
The NF2 tumor suppressor gene, located
at 22q12, is inactivated in about 40–50% of
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1995; Cheng et al., 1999). Moreover, several
cases of MM were reported in patients with
neuroﬁbromatosis 2 (Baser et al., 2002, 2005),
an autosomal dominant disorder produced by
germline mutation of the NF2 gene. In ani-
mal models, evidence suggests that disruption
of the NF2 signaling pathway plays an impor-
tant role in MM development (Altomare et al.,
2005, 2009; Fleury-Feith et al., 2003; Jongsma
et al., 2008), and several groups found altered
expression of NF2 in human MM cells (Guled
et al., 2009; Thurneysen et al., 2009). The NF2
product, Merlin, represses cyclin D1 expres-
sion, and loss/inactivation of NF2 in MM leads
to cell cycle progression in connection with
upregulation of cyclin D1 (Xiao et al., 2005).
Merlin also inhibits Rac/Pak and focal adhe-
sion kinase (FAK) signaling, which play a role
in cell migration and spreading, respectively,
and inactivation of NF2 in MM promotes cell
invasiveness and spreading (Xiao et al., 2002;
Poulikakos et al., 2006).
Homozygous deletion at CDKN2A/ARF,
a locus encoding the tumor suppressors
p16(INK4A)andp14(ARF),intheshortestregion
of overlapping deletions in 9p21, is frequently
observed in MM (Cheng et al., 1994; Ladanyi,
2005). Inhibitory binding may occur between
p16(INK4A) and the cyclin-dependent kinase
CDK4, reducing the catalytic activity of the
CDK4/cyclin D enzymes (Serrano et al., 1993).
The high rates of homozygous deletions of the
p16(INK4A) gene in cell lines from numerous
tumor types provided support for the postu-
lation that it is the tumor suppressor gene
at 9p21 (Kamb et al., 1994; Nobori et al.,
1994). Functional studies demonstrated that
reexpression of p16(INK4A) in MM cells results
in cell cycle arrest, cell death, tumor suppres-
sion,andtumorregression(Frizelleetal.,1998).
Currently,p16(INK4A)inactivationisconsidered
to be the most common genetic abnormality in
MM (Cheng et al., 1994; Ladanyi, 2005), and
it may have prognostic signiﬁcance (Illei et al.,
2003). Dacic et al. (2008) observed decreased
frequency of homozygous deletion of 9p21 and
loss of p16(INK4A) in patients with long-term
survival of greater than 3 yr, in contrast to
patients with rapidly fatal MM.
While a pathogenic role for loss of
p14(ARF) function is less well documented in
MM, adenovirus-mediated transfer of p14(ARF)
in cultured human MM cell lines was found
to induce G1-phase cell cycle arrest and
apoptotic cell death (Yang et al., 2000), sug-
gesting that p14(ARF), like p16(INK4A),i sa n
important target of 9p21 deletions in MM.
Moreover, while inactivation of p14(ARF) is
implicated as a tumor suppressor mainly in
association with the simultaneous inactivation
of p16(INK4A), heterozygous p19(Arf) mice
were recently shown to have increased sus-
ceptibility to asbestos-induced MMs compared
to wild-type littermates, and tumor forma-
tion did not require inactivation of p16Ink4a
(Altomare et al., 2009). However, deletions of
the CDKN2A/ARF locus inducing loss of both
gene products may result in a synergistic effect
with regard to MM tumorigenesis, by dereg-
ulating both the Rb and p53 pathways via
loss of p16(INK4A) and p19(ARF), respectively.
Despite the identiﬁcation of recurrent genomic
imbalances in MM, cytogenetics and in situ
hybridization have been explored for use as
diagnostic and prognostic measures with only
modest success (Dacic et al., 2008; Chiosea
et al., 2008; Factor et al., 2009; Flores-Staino
et al., 2010).
Analyses of common regions of genomic
aberrations for patterns of allele-speciﬁc hem-
izygosity need to be explored in populations
affected with MM. Some studies identiﬁed
increased risk associated with hemizygosity at
NF2 in mice, and MM arising in these mice
usually displayed loss of the remaining wild-
type allele (Fleury-Feith et al., 2003). However
beyond simple gene-dosage related changes,
in sites of recurrent loss, it is possible that the
remaining hemizygous segment, uncovered by
recurrent deletions in tumor tissue, contains
a single common underlying haplotype con-
tributing to disease etiology. Since it is likely
that the disease susceptibility locus in a sin-
gle affected population may have been inher-
ited identically by decent (IBD), genome-wide
single-nucleotide polymorphism (SNP) data in
available samples from Turkey and Italy are par-
ticularly well suited to this kind of analysis.254 J. E. BELOW ET AL.
The statistical signiﬁcance of any haplotype in
tumor tissue shared across individuals can be
determined either by permutation test or ana-
lytically, based on the haplotype frequencies
observed in the population. Patients who are
homozygous for the same underlying haplo-
types in these regions may also contribute to
the signiﬁcance of the association with disease;
combining these data may improve power
to detect important disease-associated haplo-
types. Such methods provide an additional
avenue for detection by extending the coverage
of the genome-wide marker data.
GENETIC ANALYSES
Genetic research on MM has progressed
slowly due to the rarity of the disease as well
as the difﬁculty of sample collection in such a
late-onset and highly malignant cancer. As sam-
ple collection progresses in populations and
families disproportionately affected by MM,
and collaborations develop across continents,
data sets will emerge with sufﬁcient size and
richness to identify novel susceptibility loci and
further explore the genetic pathways that have
emerged from past studies of recurrent chro-
mosomal imbalances and differential expres-
sion in human MM and mouse models of the
disease. Because genetic risk factors may be
speciﬁc to different asbestos exposures, such
studies are likely to require carefully docu-
mented ﬁber-speciﬁc exposure levels, as well as
documentation of activities and behaviors that
may affect susceptibility.
Gene Expression in Tumor Cell Lines
Cancer results from an accumulation of
genomic alterations that affect gene expres-
sion and lead to loss of cell cycle control.
With the advances in expression arrays, new
avenues are available to search genome-wide
for common effects of heterogeneous chro-
mosomal imbalances. Although several studies
attempted genome-wide expression analyses
on data sets, these have been too few to yield
conclusive results. Integrated, high-throughput
microarray-based genomic copy number and
expression analysis of normal and tumor tis-
sues from MM patients may offer a wealth of
opportunity to conduct extension and valida-
tion studies.
Genetic Association Analyses of SNP
and CNV
To date, association studies for MM focused
on candidate genes. Recently, Gemignani et al.
(2009) examined genes involved in xenobi-
otic and oxidative metabolism and found a
marginally signiﬁcant association with a SNP
in the NAT2 gene, replicating the ﬁndings
of several other groups; however, the results
are controversial. Polymorphisms in NAT2
impact N-acetylation, which in human popu-
lations segregate into fast, intermediate, and
slow acetylator phenotypes, have been asso-
ciated with several types of cancer (Roemer
et al., 2008; Weistenhofer et al., 2008; Guey
et al., 2010; Malik et al., 2009; Sobti et al.,
2009). A study of occupationally asbestos-
exposed Finnish MM patients demonstrated an
increased risk in individuals with the NAT2
slow acetylator phenotype (Hirvonen et al.,
1995, 1996) as did Gemignani et al. (2009),
while studies of Italian patients found an
increased risk of MM with the NAT2 fast acety-
lator phenotype (Neri et al., 2005). Variants
of the CYP1A1 (Neri et al., 2005, 2006),
GSTM1 (Hirvonen et al., 1995; Landi et al.,
2007), GSTT1 (Neri et al., 2006; Landi et al.,
2007), EPHX (Neri et al., 2005; 2006), XRCC1
(Dianzani et al., 2006), and XRCC3 (Dianzani
et al., 2006) genes have also been implicated
with borderline statistical signiﬁcance in candi-
date gene studies.
Studies of MM have suffered from poor
statistical power due to small sample size,
population structure, and poorly characterized
environmental exposures. Genome-wide asso-
ciation studies (GWAS) in a large, unrelated
sample set with rich data on environmental
exposures are likely to reveal common genetic
susceptibility factors segregating in affected
populations. In addition, results of GWAS in
cancer (and other complex disorders) suggest
that the genes involved with MM susceptibilityASBESTOS SUSCEPTIBILITY 255
may have quite modest effects. Therefore, to
acquire the necessary sample size for a well-
powered study, a large international collabora-
tion is required.
Spans of homozygosity may also arise in
MM patients from deletions or mitotic nondis-
junction (in which case, they are truly spans of
hemizygosity, and can be identiﬁed as spans of
reduced copy number) or through copy-neutral
events such as gene conversion, nondisjunction
followed by duplication of a parental chro-
mosome, mitotic recombination, or disease
association under a recessive model. Shared
haplotypes within spans of homo- or hemizy-
gosity in whole blood or tumor tissue among
MM patients may reveal genes important in
MM carcinogenesis, such as tumor suppressor
genes. These data provide an exciting oppor-
tunity to develop new methods for detection
and analysis of a combination of homozygosity
and hemizygosity among individuals affected
by MM.
Because somatic changes in DNA accom-
pany tumor formation and metastasis, DNA
copy number variants (CNV) need to be
assessed in tumor tissue as well as whole blood
from the same affected individuals to be geno-
typed with high-density arrays, thus providing
data on paired tumor and germline DNA from
a subset of affected individuals.
Linkage Analyses in MM-Enriched
Families
Several families in the United States have a
high incidence of MM but little or no known
asbestos exposure. Risk of MM among even
the most heavily asbestos-exposed workers is
only about 5%, indicating that a factor, per-
haps genetic, other than asbestos accounts for
the susceptibility within such families. Linkage
analyses in families with many cases of MM
as well as analyses in numerous families with
small numbers of cases are powered to identify
rare variants on shared haplotypes contribut-
ing to disease risk (Kruglyak et al., 1996). Such
analyses can complement association studies
in large data sets that are powered to detect
common variation by identifying differential
allele frequencies between unrelated cases and
controls.
NUTRITION AND ASBESTOS-RELATED
DISEASE
There is a paucity of studies examining
the relationship between diet and asbestos-
related diseases. On the other hand, con-
sumers worldwide have become increasingly
interested in how diet inﬂuences their health
and about the nutritional value and safety
of the food they eat. Evidence continues
to mount that dietary components not only
inﬂuence the ability to achieve one’s genetic
potential but also inﬂuence physical and cog-
nitive function and the risk of a number of
diseases. Unfortunately, there are numerous
inconsistencies in the available data, and few,
if any, effective strategies to identify those who
might beneﬁt from dietary intervention have
been identiﬁed. Nevertheless, support for the
Wynder and Gori (1977) suggestion more than
30 yr ago that diet was fundamental to deter-
mining cancer risk has continued, and recent
epidemiological studies clariﬁed the inﬂuence
of speciﬁc food constituents on cancer risk
and tumor behavior. The primary health effects
of asbestos exposure are related to the lung,
ranging from ﬁbrosis to lung cancer and MM.
Therefore, the focus of this section is on what is
known (or not known) about nutrients and lung
disease, and on the little that is known about
nutrients and asbestos-related diseases.
In an early case-control study of diet and
MM in Louisiana, Schiffman et al. (1988)
reported that consumption of vegetables may
have a protective effect on developing this dis-
ease, citing an inverse relationship between
MM and vegetable intake although a spe-
ciﬁc food could not be implicated nor could
the mechanism be explained. A subsequent
report on 94 men and women with MM
suggested that tomato or carrot consumption
may decrease the risk for MM (Muscat &
Huncharek, 1996). The signiﬁcant reduction in
risk of MM was associated with carrot intake
but not other carotene- or vitamin A-containing256 J. E. BELOW ET AL.
foods. The decreased risk for MM was associ-
ated with consumption of tomatoes or tomato
juice but the association did not achieve sta-
tistical signiﬁcance. Nevertheless, Muscat and
Huncharek (1996) indicated that consumption
of many vegetables and fruits might have pro-
tective effects against MM. No other studies
have been identiﬁed that further examined the
relationship between dietary components and
MM. In contrast, interest in the broader rela-
tionship between diet and cancer increased
over the last two decades, and since lung car-
cinoma continues to be the most common
cancer globally, followed by breast and colorec-
tal cancers, research has focused on the impact
of diet and its components on speciﬁc types of
cancer.
Fortes et al. (2003) reported on the
relationship between components of the
Mediterranean diet and lung cancer in a
hospital-based, case-control study of patients
admitted between 1993 and 1996. Basing
nutrient intake on self-administered food
frequency questionnaires and controlling for
smoking, data demonstrated the protective
effects for high consumption of carrots, toma-
toes, white meat, exclusive use of olive oil,
and regular consumption of sage. Data sup-
ported claims that foods rich in antioxidants
may reduce the risk for lung cancer. The
mechanisms implicated included the protec-
tion against oxidative damage to DNA and
polyphenolic compounds that prevented inter-
action of benzo[a]pyrene (BaP) with DNA.
Despite this and many other suggestive reports,
the effects of diet on cancer development or
progression remain contradictory and likely to
reﬂect variation in the ability of food compo-
nents to reach and/or modify critical cellular
targets (Milner, 2006).
Cruciferous vegetables (broccoli, cabbage,
cauliﬂower, Brussels sprouts, kale) that are rich
in isothiocyanates were postulated to reduce
the risk for lung cancer. A recently pub-
lished systematic review of the epidemiologic
literature through December 2007 identiﬁed
30 studies on the association between lung
cancer and either total cruciferous vegetable
consumption or speciﬁc cruciferous vegeta-
bles and found that the risk for lung cancer
among those in the highest category of total
cruciferous vegetable intake was 22% lower
in case-control studies compared to those in
the lowest category of intake (Lam et al.,
2009). Moreover, the strongest inverse rela-
tionship was seen among those who were
homozygous for GSTM1 and GSTT1 deletions.
Of interest is that a review of the relation-
ship between asbestos-related diseases and
genetic variability in genes involved in xeno-
biotic and oxidative metabolism or in DNA
repair processes identiﬁed increased risk with
the GSTM1-null genotype (Neri et al., 2008).
Taken together, these data suggest that compo-
nents of cruciferous vegetables may modify the
risk for asbestos-related disease in individuals
with genetic susceptibility, warranting further
investigation.
The chemopreventive potential of
β-carotene, a provitamin A carotenoid, was
supported by a number of observational
studies, leading to the initiation of several
large-scale randomized chemoprevention trials
to determine whether supplementation with
β-carotene protected against lung cancer, with
disappointing results (Omenn et al., 1996;
Virtamo et al., 2003). In fact, these trials found
that β-carotene supplementation elevated the
risk of lung cancer in high-risk populations.
Given the importance of clarifying the potential
role of carotenoids in the development of lung
cancer and the diverse body of evidence,
Gallicchio et al. (2008) conducted a system-
atic and quantitative review of randomized
clinical trials and prospective observational
studies and demonstrated that of β-carotene
supplementation was not associated with a
decrease in the risk of developing lung cancer.
The lack of association between lung cancer
risk and carotenoid intake was attributed to
the likelihood that carotenoid levels were
more of a marker of a healthier lifestyle (higher
intake of fruits and vegetables) or of residual
confounding by smoking. Studies to further
examine the effects of carotenoids on lung
cancer are not likely to be fruitful.ASBESTOS SUSCEPTIBILITY 257
Another component of food with potential
anticancer effects is the phytosterols or plant
sterols. Phytoestrols are structurally similar to
cholesterol, exist in several forms in plants,
and are found in grain legumes (sesame, chick-
peas, lentils, and peas), cereal grains (wheat,
corn, millet, rye and barley), vegetable oils
(e.g., corn), and nuts (pecans, pine, pista-
chio, peanuts, cashew, and almonds) (Woyengo
et al., 2009). Woyengo et al. (2009) concluded
that phytosterols appear to inhibit the devel-
opment of various cancers by inhibiting pro-
liferation and promoting apoptosis of cancer
cells through the activation of caspase enzymes
and may reduce cancer development by lower-
ing blood cholesterol and consequently altering
cell membranes. Further study of the potential
role of phytosterols in humans is required.
A number of other foods or food com-
ponents have been studied and not shown
to inﬂuence cancer risk, including garlic (Kim
and Kwon, 2009) and vitamins A, E, C, and
folate (Cho et al., 2006). Flavonoids, a group
of potentially chemoprotective compounds
widely distributed in fruit, vegetables, and
beverages of plant origin, have also been stud-
ied as the potential active ingredient respon-
sible for the reduction of cancer risk. In their
analysis of data from the Nurses’ Health Study,
Wang et al. (2009) did not ﬁnd a signiﬁcant
role for ﬁve common ﬂavonols and ﬂavones
or selected ﬂavonoid-rich foods in cancer pre-
vention. In a small case-control study, dietary
zinc and copper, but not selenium, appeared
to be associated with lower risk for lung cancer
(Mahabir et al., 2007).
Finally, a few words about nutrition in
early life: It is well accepted that environ-
mental exposures play a signiﬁcant role in the
etiology of disease. Such exposures usually pre-
cede the appearance of clinical disease, often
by a prolonged period of time. Besides the
role of genetic mutations, epigenetic processes
such as DNA methylation and covalent mod-
iﬁcation of histones are likely to play a role
in alterations in gene activity that may con-
tribute to risk for some types of cancer. Burdge
et al. (2009) provided a compelling hypothesis
that increased susceptibility to certain disease,
including cancer, may have a common origin in
developmental changes induced by epigenetic
changes induced by environmental exposures,
which includes nutrition. The maternal diet,
including nutrients known to affect methyla-
tion reactions such as folate, vitamin B12,a n d
sulfur amino acids, may impact the develop-
ing fetus and contribute to disease susceptibility
later in life. This is an important area of future
investigation as interest increases with regard
to how nutrients inﬂuence the development or
susceptibility to multiple diseases.
In summary, in the area of the impact of
nutrients on asbestos-related diseases, little is
known and even less is being investigated.
However, because of the increasing awareness
that nutrients play an important role in the
onset and development of disease and because
of the ever-changing food supply as we face a
global economy, it seems highly worthwhile to
begin to support active research in this area.
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